Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company NeoPharm has said that a phase II trial in second-line metastatic colorectal cancer patients with its product LE-SN38, failed to produce the desired results.
Subscribe to our email newsletter
While the interim analysis of data following the completion of treatment of the first 21 patients demonstrated disease stabilization, the study did not achieve the primary tumor response endpoint. NeoPharm said no new patient accrual will be made into this study.
Patients currently receiving therapy will continue treatment per protocol until a study endpoint is reached. NeoPharm said it will be reassessing project next steps including additional data analyses and the possibility of other studies.